Strong growth in the recombinant AAV (rAAV)-based gene therapy sector is creating a need for dramatically increased production of rAAV vectors. Physically increasing manufacturing capacity is neither sufficient or cost-effective. In this webinar, Dr Lisa Prendergast will review how Lonza has further improved its suspension HEK293 based platform with engineered plasmids. These afford significantly higher titers and productivity levels compared to standard systems. These technologies have now been incorporated in Xcite™ AAV, our suspension rAAV manufacturing platform and it is now available to take to your labs.
Key learning objectives:
- AAV productivity can be optimized using platform technologies
- Lonza has developed improved and rebalanced Helper and RepCap plasmids that can help increase AAV titer
- The Xcite™ AAV Platform Technology is now available to out-license